» Articles » PMID: 29391790

Targeting Prostate Cancer Cells with Hybrid Elastin-like Polypeptide/liposome Nanoparticles

Overview
Publisher Dove Medical Press
Specialty Biotechnology
Date 2018 Feb 3
PMID 29391790
Citations 10
Authors
Affiliations
Soon will be listed here.
Abstract

Prostate cancer cells frequently overexpress the gastrin-releasing peptide receptor, and various strategies have been applied in preclinical settings to target this receptor for the specific delivery of anticancer compounds. Recently, elastin-like polypeptide (ELP)-based self-assembling micelles with tethered GRP on the surface have been suggested to actively target prostate cancer cells. Poorly soluble chemotherapeutics such as docetaxel (DTX) can be loaded into the hydrophobic cores of ELP micelles, but only limited drug retention times have been achieved. Herein, we report the generation of hybrid ELP/liposome nanoparticles which self-assembled rapidly in response to temperature change, encapsulated DTX at high concentrations with slow release, displayed the GRP ligand on the surface, and specifically bound to GRP receptor expressing PC-3 cells as demonstrated by flow cytometry. This novel type of drug nanocarrier was successfully used to reduce cell viability of prostate cancer cells in vitro through the specific delivery of DTX.

Citing Articles

PEGylated Nanoliposomes Encapsulated with Anticancer Drugs for Breast and Prostate Cancer Therapy: An Update.

Peter S, Khwaza V, Alven S, Naki T, Aderibigbe B Pharmaceutics. 2025; 17(2).

PMID: 40006557 PMC: 11859135. DOI: 10.3390/pharmaceutics17020190.


Potential Application of Self-Assembled Peptides and Proteins in Breast Cancer and Cervical Cancer.

Zhang S, Chen M, Geng Z, Liu T, Li S, Yu Q Int J Mol Sci. 2023; 24(23).

PMID: 38069380 PMC: 10706889. DOI: 10.3390/ijms242317056.


Nanotherapeutic Approach to Delivery of Chemo- and Gene Therapy for Organ-Confined and Advanced Castration-Resistant Prostate Cancer.

Sharma S, Mahajan S, Chevli K, Schwartz S, Aalinkeel R Crit Rev Ther Drug Carrier Syst. 2023; 40(4):69-100.

PMID: 37075068 PMC: 11007628. DOI: 10.1615/CritRevTherDrugCarrierSyst.2022043827.


Nanostrategies for Therapeutic and Diagnostic Targeting of Gastrin-Releasing Peptide Receptor.

Rurarz B, Bukowczyk M, Gibka N, Piastowska-Ciesielska A, Karczmarczyk U, Ulanski P Int J Mol Sci. 2023; 24(4).

PMID: 36834867 PMC: 9958678. DOI: 10.3390/ijms24043455.


Recent Trends and Developments in Multifunctional Nanoparticles for Cancer Theranostics.

Rabaan A, Bukhamsin R, AlSaihati H, Alshamrani S, AlSihati J, Al-Afghani H Molecules. 2022; 27(24).

PMID: 36557793 PMC: 9780934. DOI: 10.3390/molecules27248659.


References
1.
Huwyler J, Drewe J, Krahenbuhl S . Tumor targeting using liposomal antineoplastic drugs. Int J Nanomedicine. 2008; 3(1):21-9. PMC: 2526358. View

2.
OHanlon Brown C, Waxman J . Current management of prostate cancer: dilemmas and trials. Br J Radiol. 2012; 85 Spec No 1:S28-40. PMC: 3746401. DOI: 10.1259/bjr/13017671. View

3.
Reid A, Attard G, Danila D, Oommen N, Olmos D, Fong P . Significant and sustained antitumor activity in post-docetaxel, castration-resistant prostate cancer with the CYP17 inhibitor abiraterone acetate. J Clin Oncol. 2010; 28(9):1489-95. PMC: 2849770. DOI: 10.1200/JCO.2009.24.6819. View

4.
Funakoshi Y, Iwao Y, Noguchi S, Itai S . Effect of Alkyl Chain Length and Unsaturation of the Phospholipid on the Physicochemical Properties of Lipid Nanoparticles. Chem Pharm Bull (Tokyo). 2015; 63(9):731-6. DOI: 10.1248/cpb.c15-00077. View

5.
Zhang J, Anyarambhatla G, Ma L, Ugwu S, Xuan T, Sardone T . Development and characterization of a novel Cremophor EL free liposome-based paclitaxel (LEP-ETU) formulation. Eur J Pharm Biopharm. 2004; 59(1):177-87. DOI: 10.1016/j.ejpb.2004.06.009. View